Pharmacology of selegiline

Neurology

Volumn 47, Issue 6 SUPPL. 3, 1996, Pages

  Gerlach, M ^a   Youdin, M B H ^b   Riederer, P ^a,c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; METHAMPHETAMINE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SELEGILINE;

ARTICLE; CATECHOLAMINE NERVE CELL; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG SELECTIVITY; HUMAN; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ANTIPARKINSON AGENTS; SELEGILINE;

EID: 0029774181     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. Knoll J, Ecseri Z, Kelemen K, et al. Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther 1965;155:154-164.
2. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968; 17:1285-1297.
3. Knoll J, Magyar K. Some puzzling effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 1972;5:393-408.
4. Magyar K, Vizi ES, Esceri Z, et al. Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methylpropinylamine (E-250). Acta Physiol Hung 1967;32:377-387.
5. Reynolds GP, Elsworth JD, Blau K, et al. Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol 1978;6:542-544.
6. Taylor KM, Snyder SH. Amphetamine: differentiation by D and L isomers of behavior involving brain norepinephrine or dopamine. Science 1974;168:1487-1489.
7. Knoll J. Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand 1983;68(suppl 95):57-80.
8. Heinonen EH, Myllylä V, Sotaniemi K, et al. Pharmacokinetics and metabolism of selegiline. Acta Neurol Scand 1989;126: 93-99.
9. Schacter M, Marsden CD, Parkes JD, et al. Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. J Neurol Neurosurg Psychiatry 1980;43:1016-1021.
10. Magyar K, Tothfalusi L. Pharmacokinetic aspects of deprenyl effects. Pol J Pharmacol Pharm 1984;36:373-384.
11. Riederer P, Youdim MBH, Rausch WD, et al. On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm 1978;43:217-226.
12. Meeker JE, Reynolds PC. Postmortem tissue methamphetamine concentrations following selegiline administration. J Anal Toxicol 1990;14:330-331.
13. Beckett AH, Rowland M. Urinary excretion kinetics of amphetamine in man. J Pharm Pharmacol 1965;17:628-639.
14. Elsworth JD, Sandler M, Lees AJ, et al. The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties. J Neural Transm 1982;54:105-110.
15. 11C-labeled suicide inactivators and PET. Science 1987;235:481-485.
16. Reynolds GP, Riederer P, Sandler M, et al. Amphetamine and phenylethylamine in post-mortem Parkinson's brain after (-)deprenyl administration. J Neural Transm 1978;43:271-277
17. Yoshida D, Yamada Y, Yamamoto T, et al. Metabolism of deprenyl, a selective monoamine oxidase inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency. Xenobiotica 1986;16:129-136.
18. Yoshida D, Oguru T, Kuroiwa Y. Hepatic and extrahepatic metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor, of amphetamine in rats: sex and strain differences. Xenobiotica 1987;17:957-963.
19. Youdim MBH, Finberg JPM, Tipton KF. Monoamine oxidase. In: Trendelenburg U, Weiner N, eds. Catecholamines I, handbook of experimental pharmacology, vol. 90/1, Berlin: Springer, 1988:119-192.
20. Blaschko H. Amine oxidase and amine metabolism. Pharmacol Rev 1952;4:415-453.
21. De Varebeke PJ, Cavalier R, David-Remacle M, et al. Formation of the neurotransmitter glycine from the anticonvulsant milacemide is mediated by brain monoamine oxidase B. J Neurochem 1988;50:1011-1016.
22. Chiba K, Trevor A, Castagnoli N Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984;120:574-578.
23. Heikkila RE, Manzino L, Cabbat FS, et al. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984;311:467-469.
24. 3H]Harman labels selectively and with high affinity the active site of monoamine oxidase (EC 1.4.3.4) subtype A (MAO-A) in rat, marmoset, and pig. J Neural Transm 1990;32(suppl):93-102.
25. Westlund KN. The distribution of monoamine oxidases A and B in normal human brain. In: Lieberman A, Olanow CW, Youdim MBH, Tipton, eds. Monoamine oxidase inhibitors in neurological diseases. New York: Marcel Dekker, 1994:1-19.
26. O'Carroll A-M, Fowler CJ, Phillips JP, et al. The deamination of dopamine by human brain monoamine oxidase: specificity for the two enzyme forms in seven brain regions. Naunyn Schmiedebergs Arch Pharmacol 1983;322:198-202.
27. Riederer P, Youdim MBH. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with L-deprenyl. J Neurochem 1986;46:1359-1365.
28. Fowler JS, Volkow ND, Logan J, et al. Slow recovery of human brain MAO after L-deprenyl (selegiline) withdrawal. Synapse 1994;18:86-93.
29. Heikkila RE, Terleckyj I, Sieber BA. Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: relevance to DATATOP. J Neural Transm 1990;32(suppl):217-227.
30. Ekstedt B, Magyar K, Knoll J. Does the B form selective monoamine oxidase inhibitor deprenyl lose selectivity by long term treatment? Biochem Pharmacol 1978;28:919-923.
31. Knoll J. The possible mechanisms of action of (-)deprenyl in Parkinson's disease. J Neural Transm 1978;43:177-198.
32. Waldmeier PC, Felner AE. Deprenyl, loss of selectivity for inhibition of B-type MAO after repeated treatment. Biochem Pharmacol 1978;27:801-802.
33. Schulz R, Antonin K-H, Hiffmann E, et al. Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clin Pharmacol Ther 1989;46:528-536.
34. Riederer P, Jellinger K, Seemann D. Monoamine oxidase and parkinsonism. In: Tipton K, Dostert P, Strolin-Benedetti M, eds. Monoamine oxidase and disease. San Diego: Academic Press, 1984:404-415.
35. Green AR, Mitchell B, Tordorff A, et al. Evidence that dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of enzyme inhibition necessary to increase functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol 1977;60:343-349.
36. Braestrup C, Andersen H, Randrup A. The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation. Eur J Pharmacol 1978;34:181-188.
37. Knoll J. R-(-)-Deprenyl (selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron. J Neural Transm 1987;25(suppl):45-66.
38. Trendelenburg U, Draskoczy, Graefe KH. The influence of intraneuronal monoamine oxidase on neuronal net uptake of noradrenaline and on sensitivity to noradrenaline. Adv Biochem Psychopharmacol 1972;5:371-378.
39. Finberg JPM, Tenne M, Youdim MBH. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol 1981;73:65-74.
40. Gerlach M, Riederer P, Youdim MBH. The molecular pharmacology of L-deprenyl. Eur J Pharmacol, Mol Pharmacol Section 1992;226:97-108.
41. Knoll J, Miklya I, Knoll B, et al. (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential transmitter release coupling in the catecholaminergic neurons. Life Sci 1996;58:817-827.
42. Knoll J, Ecsery Z, Magyar K, et al. Novel (-)-deprenyl-derived selective inhibitors of B-type monoamine oxidase: the relation of structure to their action. Biochem Pharmacol 1978;27: 1739-1746.
43. Gerlach M, Riederer P, Youdim MBH. Molecular mechanisms for neurodegeneration: synergism between reactive oxygen species, calcium and excitotoxic amino acids. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S, eds. Advances in neurology, vol. 69, Parkinson's disease. Philadelphia: Lippincott-Raven, 1996:177-194.
44. Gerlach M, Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 1996 (in press).
45. Gerlach M, Riederer P, Przuntek, et al. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol, Mol Pharmacol Section 1991;208:273-286.
46. Knoll J. The pharmacology of (-)deprenyl. J Neural Transm 1986;22(suppl):75-89.
47. Pattichis K, Louca LL, Clow A, et al. Effects of pergolide, (-)-deprenyl and thioridazine on soluble SOD, catalase and glutathione peroxidase in rat striata. Med Sci Res 1995;23: 733-735.
48. Ben-Yoseph O, Boxer PA, Ross BD. Assessment of the role of the glutathione and pentose phosphate pathways in the protection of primary cerebrocortical cultures from oxidative stress. J Neurochem 1996;66:2329-2337.
49. Knoll J. The striatal dopamine dependency of life span in male rats: longevity study with (-)deprenyl. Mech Ageing Dev 1988;46:237-262.
50. Carrillo M-C, Kanai S, Nokubo M, et al. (-)Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 1991;48:517-521.
51. Clow A, Hussain T, Glover V, et al. (-)-Deprenyl can induce soluble superoxide dismutase in rat striata. J Neural Transm Gen Sect 1991;86:77-80.
52. Kushleika J, Checkoway H, Woods JS, et al. Selegiline and lymphocyte superoxide dismutase activities in Parkinson's disease. Ann Neurol 1996;39:378-381.
53. Tolmasoff JM, Ono T, Cutler RG. Superoxide dismutase: correlation with lifespan and specific metabolite rate in primate species. Proc Natl Acad Sci USA 1980;77:2777-2781.
54. Sohal RS, Farmer KJ, Allen RG. Correlates of longevity in two strains of the housefly, Musca domestica. Mech Ageing Dev 1987;40:171-179.
55. Przedborski S, Kostic V, Jackson-Lewis V, et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci 1992;12:1658-1667.
56. Albino-Teixeira A, Azevedo I, Martel F, et al. Superoxide dismutase partially prevents sympathetic denervation by 6-hydroxydopamine. Arch Pharmacol 1991;244:36-40.
57. Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991;30:666-672.
58. +-treated dopaminergic neurons. Eur J Pharmacol, Mol Pharmacol Section 1994;269:R3-R4.
59. Koutsilieri E, Chen T-S, Rausch W-D, et al. Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridinium. Eur J Pharmacol, Mol Pharmacol Section 1996;306:181-186.
60. Salo PT, Tatton WG. Deprenyl reduces the death of motor neurons caused by axotomy. J Neurosci Res 1992;31:394-400.
61. Beck KD, Valverde J, Alexi T, et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 1995;373:339-341.
62. + toxicity. EMBO J 1995;14:736-742.
63. Biagini G, Zoll M, Fuxe K, et al. L-Deprenyl increases GFAB immunoreactivity selectively in activated astrocytes in rat brain. Neuroreport 1993;5:955-958.
64. Biagini G, Frasoldati A, Fuxe K, et al. The concept of astrocyte-kinetic drug in the treatment of neurodegenerative diseases: evidence for L-deprenyl-induced activation of reactive astrocytes. Neurochem Int 1994;25:17-22.
65. Giulian D, Vaca K, Corpuz M. Brain glia release factors with opposing actions upon neuronal survival. J Neurosci 1993;13: 29-37.
66. Hou JGG, Lin LFH, Mytilineou C. Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium. J Neurochem 1996;66:74-82.
67. Birkmayer W, Riederer P, Youdim MBH, et al. The potentiation of the antiakinetic effect after L-dopa treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 1975;36:303-326.
68. Youdim MBH, Collins GGS, Sandler M, et al. Human brain monoamine oxidase: multiple forms and selective inhibition. Nature 1972;236:225-228.
69. Squires RF. Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species. Adv Biochem Psychopharmacol 1972;5:355-370.
70. Elizan TS. (-)-Deprenyl combined with L-dopa in the treatment of Parkinson's disease. In: Szelenyi I, ed. Inhibitors of monoamine oxidase B: pharmacology and clinical use in neurodegenerative disorders. Basel: Birkhäuser Verlag, 1993; 277-288.
71. Paterson IA, Juorio AV, Boulton AA. 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system? J Neurochem 1990;55:1827-1837.
72. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-1371.
73. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989; 245:519-522.
74. Birkmayer W, Knoll J, Riederer P, et al. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a long-term study. J Neural Transm 1985;64:113-127.
75. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-184.
76. Przuntek H. Clinical aspects of neuroprotection in Parkinson's disease. J Neural Transm 1994;43(suppl):163-169.
77. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-777.
78. Tipton KF. What is it that L-deprenyl (selegiline) might do? Clin Pharmacol Ther 1994;56(suppl):781-796.
79. Chiueh CC, Huang S-J, Murphy DL. Suppression of hydroxyl radical formation by MAO inhibitors: a novel neuroprotective mechanism in dopaminergic neurotoxicity. J Neural Transm 1994;42(suppl):189-196.
80. Gerlach M, Desser H, Youdim MBH, et al. New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline. J Neural Transm 1996 (suppl) (in press).
81. Williams K, Romano C, Dichter MA, et al. Modulation of the NMDA receptor by polyamines. Life Sci 1991;48:469-479.
82. Beart PM, Schousboe A, Frandsen A. Blockade by polyamine NMDA antagonists related to ifenprodil of NMDA-induced synthesis of cylic GMP, increases in calcium and cytotoxicity in cultured neurones. Br J Pharmacol 1995;114:1359-1364.
83. The Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996;39:29-36.